You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 6, June 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Nutritional and Metabolic Disorders, Other
 •Diagnosis
 •Articles for Residents
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Sclerochoroidal Calcification

Clinical Manifestations and Systemic Associations

Santosh G. Honavar, MD; Carol L. Shields, MD; Hakan Demirci, MD; Jerry A. Shields, MD

Arch Ophthalmol. 2001;119:833-840.

Background  Sclerochoroidal calcification is an unusual ocular condition that is believed to be idiopathic in most cases.

Objectives  To describe the clinical manifestations of sclerochoroidal calcification and to investigate its possible systemic associations.

Methods  This noncomparative consecutive case series included patients diagnosed as having sclerochoroidal calcification based on clinical characteristics and diagnostic test findings. We analyzed the demographic, systemic, and ocular features of 27 such patients. Systemic evaluation included tests for calcium-phosphorus metabolism in 19 patients and renal tubular hypokalemic metabolic alkalosis syndromes (Bartter or Gitelman syndrome) in 13.

Results  All the patients were asymptomatic older (mean age, 70 years) white individuals, incidentally noted as having a choroidal lesion on routine examination. Among 38 eyes, the main referral diagnoses were choroidal metastasis in 10 eyes (26%), choroidal melanoma in 8 (21%), and choroidal nevus in 4 (11%). Sixteen patients (59%) had unilateral clinical findings, while 11 (41%) had bilateral. The Snellen visual acuity was 20/50 or better in 37 eyes (97%). Cogan scleral plaque was visible anterior to the insertion of horizontal rectus muscles in 10 eyes (26%). Among 77 foci, there were a mean of 2 foci of sclerochoroidal calcification in each eye, 41 yellow (53%), 32 yellow-white (42%), 2 white (3%), and 2 orange (3%), measuring a mean 2.6 mm in diameter and 1.1 mm in thickness. The most common locations were postequatorial in 45 (58%), along the temporal vascular arcades in 30 (39%), and in the superotemporal quadrant in 43 (56%). A-scan and B-scan ultrasonography revealed dense echoes compatible with calcium, with orbital shadowing. All the lesions remained stable in size and configuration during a mean follow-up of 38 months. One patient developed a choroidal neovascular membrane over the area of sclerochoroidal calcification. Investigations for abnormal calcium-phosphorus metabolism in 19 patients revealed primary hyperparathyroidism in 1 patient (5%). Clinical and biochemical evaluation of 13 patients demonstrated hypomagnesemia in 6 (46%). Four patients (31%) met the criteria for the diagnosis of Gitelman syndrome.

Conclusions  Sclerochoroidal calcification usually manifests as multiple discrete yellow placoid lesions in the midperipheral fundus of asymptomatic older white individuals. Although most cases may be idiopathic in nature, some patients may have underlying systemic disorders involving abnormal calcium-phosphorus metabolism or renal tubular hypokalemic metabolic alkalosis syndromes. All patients with sclerochoroidal calcification should be tested for these treatable systemic associations.


From the Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pa (Drs Honavar, C. L. Shields, Demirci, and J. A. Shields), and Ocular Oncology Service, L.V. Prasad Eye Institute, Hyderabad, India (Dr Honavar).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(6):931-932.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease
Richette et al.
Rheumatology (Oxford) 2009;48:711-715.
ABSTRACT | FULL TEXT  

Choroidal osteoma in association with Stargardt's dystrophy
Figueira et al.
Br J Ophthalmol 2007;91:978-979.
FULL TEXT  

Factors Predictive of Tumor Growth, Tumor Decalcification, Choroidal Neovascularization, and Visual Outcome in 74 Eyes With Choroidal Osteoma
Shields et al.
Arch Ophthalmol 2005;123:1658-1666.
ABSTRACT | FULL TEXT  

Sclerochoroidal calcification associated with Gitelman syndrome and calcium pyrophosphate dihydrate deposition
Gupta et al.
J. Clin. Pathol. 2005;58:1334-1335.
ABSTRACT | FULL TEXT  

Idiopathic sclerochoroidal calcification
Cooke et al.
Br J Ophthalmol 2003;87:245-246.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.